A detailed history of Krs Capital Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Krs Capital Management, LLC holds 12,041 shares of BMY stock, worth $671,526. This represents 0.46% of its overall portfolio holdings.

Number of Shares
12,041
Previous 10,914 10.33%
Holding current value
$671,526
Previous $453,000 37.53%
% of portfolio
0.46%
Previous 0.34%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$39.66 - $51.75 $44,696 - $58,322
1,127 Added 10.33%
12,041 $623,000
Q2 2024

Jul 17, 2024

SELL
$40.25 - $52.99 $134,676 - $177,304
-3,346 Reduced 23.46%
10,914 $453,000
Q1 2024

Apr 16, 2024

SELL
$47.98 - $54.4 $10,027 - $11,369
-209 Reduced 1.44%
14,260 $773,000
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $53,618 - $63,982
-1,106 Reduced 7.1%
14,469 $742,000
Q3 2023

Oct 19, 2023

SELL
$57.89 - $64.73 $49,495 - $55,344
-855 Reduced 5.2%
15,575 $903,000
Q2 2023

Jul 14, 2023

BUY
$63.71 - $70.74 $7,772 - $8,630
122 Added 0.75%
16,430 $1.05 Million
Q1 2023

Apr 11, 2023

BUY
$65.71 - $74.53 $14,390 - $16,322
219 Added 1.36%
16,308 $1.13 Million
Q4 2022

Jan 19, 2023

BUY
$68.48 - $81.09 $51,565 - $61,060
753 Added 4.91%
16,089 $0
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $10 - $6,147
80 Added 0.52%
15,336 $1.09 Million
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $6,463 - $7,118
89 Added 0.59%
15,256 $1.17 Million
Q1 2022

Apr 27, 2022

SELL
$61.48 - $73.72 $4,119 - $4,939
-67 Reduced 0.44%
15,167 $1.11 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $816,999 - $952,429
15,234 New
15,234 $949,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Krs Capital Management, LLC Portfolio

Follow Krs Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krs Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krs Capital Management, LLC with notifications on news.